BIOMARKER:

MET amplification

News alerts, weekly reports and conference planners

Entrez ID:

4233

Related biomarkers:

‹

›

MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) REGN5093 Sensitive : C2 ESMO 2022 - 3wk	REGN5093 Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks REGN5093 Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2	savolitinib Sensitive: A2 - Guideline savolitinib Sensitive : A2
MET amplification	Gastroesophageal Junction Adenocarcinoma	MET amplification	Gastroesophageal Junction Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B	AMG 102 Resistant: B - Late Trials AMG 102 Resistant : B
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2	bevacizumab + crizotinib Sensitive: C2 – Inclusion Criteria bevacizumab + crizotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	SCC244 Sensitive: C2 – Inclusion Criteria SCC244 Sensitive : C2	SCC244 Sensitive: C2 – Inclusion Criteria SCC244 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2	gefitinib + CT053PTSA Sensitive: C2 – Inclusion Criteria gefitinib + CT053PTSA Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET amplification	Lung Cancer	MET amplification	Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2	APL-101 Sensitive: C2 – Inclusion Criteria APL-101 Sensitive : C2
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	capmatinib Sensitive: C2 – Inclusion Criteria capmatinib Sensitive : C2	capmatinib Sensitive: C2 – Inclusion Criteria capmatinib Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2	savolitinib Sensitive: C2 – Inclusion Criteria savolitinib Sensitive : C2
MET amplification	Renal Cell Carcinoma	MET amplification	Renal Cell Carcinoma	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification	Head and Neck Cancer	MET amplification	Head and Neck Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification	Gastric Adenocarcinoma	MET amplification	Gastric Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MET amplification	Gallbladder Cancer	MET amplification	Gallbladder Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3
MET amplification	Colorectal Cancer	MET amplification	Colorectal Cancer	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3	TPX-0022 Sensitive: C3 – Early Trials TPX-0022 Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3	gefitinib + savolitinib Sensitive: C3 – Early Trials gefitinib + savolitinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
MET amplification	Solid Tumor	MET amplification	Solid Tumor	TQ-B3101 Sensitive: C3 – Early Trials TQ-B3101 Sensitive : C3	TQ-B3101 Sensitive: C3 – Early Trials TQ-B3101 Sensitive : C3
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification	Lung Adenocarcinoma	MET amplification	Lung Adenocarcinoma	crizotinib + osimertinib Sensitive: C3 – Early Trials crizotinib + osimertinib Sensitive : C3	crizotinib + osimertinib Sensitive: C3 – Early Trials crizotinib + osimertinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
MET amplification	Gastroesophageal Cancer	MET amplification	Gastroesophageal Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification	Lung Adenocarcinoma	MET amplification	Lung Adenocarcinoma	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3
MET amplification	Colorectal Cancer	MET amplification	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3

MET amplification

Associations